JP2024508824A5 - - Google Patents
Info
- Publication number
- JP2024508824A5 JP2024508824A5 JP2023551999A JP2023551999A JP2024508824A5 JP 2024508824 A5 JP2024508824 A5 JP 2024508824A5 JP 2023551999 A JP2023551999 A JP 2023551999A JP 2023551999 A JP2023551999 A JP 2023551999A JP 2024508824 A5 JP2024508824 A5 JP 2024508824A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gpam
- guanine
- complement
- position corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163154693P | 2021-02-27 | 2021-02-27 | |
| US63/154,693 | 2021-02-27 | ||
| PCT/US2022/017899 WO2022182985A1 (en) | 2021-02-27 | 2022-02-25 | Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (gpam) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508824A JP2024508824A (ja) | 2024-02-28 |
| JP2024508824A5 true JP2024508824A5 (https=) | 2025-01-27 |
Family
ID=80786652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551999A Pending JP2024508824A (ja) | 2021-02-27 | 2022-02-25 | ミトコンドリアグリセロール－３－リン酸アシルトランスフェラーゼ（ｇｐａｍ）阻害剤による肝疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12215322B2 (https=) |
| EP (1) | EP4297772A1 (https=) |
| JP (1) | JP2024508824A (https=) |
| KR (1) | KR20230151996A (https=) |
| CN (1) | CN116867510A (https=) |
| AU (1) | AU2022227748A1 (https=) |
| CA (1) | CA3210481A1 (https=) |
| IL (1) | IL304543A (https=) |
| MX (1) | MX2023009986A (https=) |
| WO (1) | WO2022182985A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010000656A1 (en) | 2008-07-03 | 2010-01-07 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1) |
| US9149445B2 (en) | 2009-07-27 | 2015-10-06 | The Trustees Of Princeton University | Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections |
| US11702394B2 (en) | 2018-02-23 | 2023-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
| WO2021252649A2 (en) * | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression |
-
2022
- 2022-02-25 EP EP22711374.3A patent/EP4297772A1/en active Pending
- 2022-02-25 KR KR1020237027859A patent/KR20230151996A/ko active Pending
- 2022-02-25 US US17/680,940 patent/US12215322B2/en active Active
- 2022-02-25 CN CN202280016246.0A patent/CN116867510A/zh active Pending
- 2022-02-25 MX MX2023009986A patent/MX2023009986A/es unknown
- 2022-02-25 AU AU2022227748A patent/AU2022227748A1/en active Pending
- 2022-02-25 WO PCT/US2022/017899 patent/WO2022182985A1/en not_active Ceased
- 2022-02-25 JP JP2023551999A patent/JP2024508824A/ja active Pending
- 2022-02-25 CA CA3210481A patent/CA3210481A1/en active Pending
-
2023
- 2023-07-18 IL IL304543A patent/IL304543A/en unknown
-
2024
- 2024-12-23 US US19/000,435 patent/US20250197866A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11028393B2 (en) | siRNA compositions that specifically down regulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease | |
| JP2020536560A5 (https=) | ||
| JP2024502282A5 (https=) | ||
| Khan et al. | Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics | |
| US12612665B2 (en) | Long non-coding RNA LETN serving as tumor marker and therapeutic target point | |
| JP2022523301A5 (https=) | ||
| KR20060029597A (ko) | Ｒｎａ 간섭에 기반한 ｈｂｖ 유전자 발현의 억제 방법 및조성물 | |
| JP2023531935A5 (https=) | ||
| JP7553036B2 (ja) | ｓｎｏＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| Poma et al. | Analysis of possible mechanisms accounting for raf-1 kinase inhibitor protein downregulation in hepatocellular carcinoma | |
| Asamoto et al. | Transgenic rats carrying human c-Ha-ras proto-oncogenes are highly susceptible to N-methyl-N-nitrosourea mammary carcinogenesis | |
| JP2023543763A5 (https=) | ||
| Ouna et al. | Depletion of trypanosome CTR9 leads to gene expression defects | |
| JP2023539742A5 (https=) | ||
| JP2024508824A5 (https=) | ||
| JP2023536814A5 (https=) | ||
| JP2022525545A5 (https=) | ||
| Zhang et al. | The proline-rich acidic protein is epigenetically regulated and inhibits growth of cancer cell lines | |
| JP2022529917A5 (https=) | ||
| JP2022525546A5 (https=) | ||
| JP2024528284A5 (https=) | ||
| JP2025503594A5 (https=) | ||
| JP2024531507A5 (https=) | ||
| JP2022515838A5 (https=) | ||
| CN110846413B (zh) | Mafg/mafg-as1/mafg正反馈环作为靶位点检测试剂的应用 |